The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.
Subjects who can understand and are willing to complying with protocol requirement and sign the informed consent form.
Man or woman aged 18 years to 75 years (inclusive), with BMI≤30 kg/m2.
Patients with moderate to severe hypertension. Untreated patients must have an msSBP ≥ 160 mmHg and < 190 mmHg at the screening and randomization visit; Treated patients must have an msSBP≥150 mmHg and <180 mmHg or msSBP≥140 mmHg and <170 mmHg at the screening visit based on numbers of antihypertensive and msSBP≥160 mmHg <190 mmHg at the randomization visit; Patients must have an absolute difference of ≤20 mmHg in msSBP between randomization visit and the immediately preceding visit.
Subjects who agree to use adequate contraception from 2 weeks prior to screening to 1 month after last dose.
History or evidence of a secondary form of hypertension.
History of peripheral arterial occlusive disease and Raynaud's syndrome.
History of hyperthyroidism.
History of hypotension.